Domestic drug makers skimping on R&D investment

Published: 2007-11-05 06:54:00

Updated: 2007-11-05 06:54:00

Despite their relatively large assets, the nation’s 34 Korean pharmaceutical companies spend considerably less on research and development (R&D) than promotional expenses, industry data showed recently.

According to the Korea Health Industry Development Institute data submitted to Rep. Ahn Myung-Ok of the Grand National Party, R&D spending of 34 local firms listed in Korean Stock Exchange st...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.